On World Parkinson's Day (#worldparkinsonsday), Healthware Group is proud to announce its involvement in a recent study that advances the understanding of Parkinson's disease (PD) symptom detection. The study, funded by Orion Corporation and supported by Healthware Group, was published in the PLOS Digital Health journal on April 7, 2023.
The study, titled "Feasibility and patient acceptability of a commercially available wearable and a smartphone application in identification of motor states in Parkinson's disease," explored the use of commercially available smartphones and wearable devices to detect PD symptoms. A total of 42 PD patients and 23 control subjects were monitored for about four weeks using a Garmin Vivosmart 4 wearable device and asked to fill a symptom and medication diary with a mobile application, developed by Healthware Group's investment company, Newel Health.
This innovative research aims to address the challenges in continuous, longitudinal, and automated detection of motor and non-motor symptoms in PD patients. The data collected from everyday life is often noisy and contains artifacts, emphasizing the need for novel detection methods and algorithms.
Building on the success of this research, Newel Health is currently working on a digital therapeutic (DTx) product named Soturi, specifically designed for Parkinson's disease patients. Soturi promises to enhance the quality of life for individuals living with PD by improving symptom detection and management.
Newel Health is dedicated to leveraging technology and innovation to improve patient outcomes and raise awareness about Parkinson's disease. The company remains committed to supporting groundbreaking research and fostering collaboration with partners like Orion Corporation to make a meaningful difference in the lives of those affected by this disease.
For more information about the study, please visit: https://doi.org/10.1371/journal.pdig.0000225